National Academies Press: OpenBook
« Previous: Appendix A: Statement of Task
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. The Role of NIH in Drug Development Innovation and Its Impact on Patient Access: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25591.
×
Page 59
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. The Role of NIH in Drug Development Innovation and Its Impact on Patient Access: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25591.
×
Page 60
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. The Role of NIH in Drug Development Innovation and Its Impact on Patient Access: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25591.
×
Page 61
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2019. The Role of NIH in Drug Development Innovation and Its Impact on Patient Access: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25591.
×
Page 62

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix B Workshop Agenda WEDNESDAY, JULY 24, 2019 8:00 am Registration 8:45 am Welcome and Workshop Overview Jeff Bingaman, J.D., Planning Committee Chair 9:00 am SESSION 1: Keynote Address Moderator: Jeff Bingaman, J.D., Former U.S. Senator, New Mexico Overview of the Translational Research Landscape Christopher Austin, M.D., National Center for Advancing Translational Sciences, National Institutes of Health (NIH) Open Discussion 10:00 am Break 10:15 am SESSION 2: Federal Funding for Biomedical Research and Its Contributions to New Drug Development and Commercialization Moderator: Amitabh Chandra, Ph.D., Harvard University Session Objective: To discuss the impacts of publicly funded biomedical research and ways to better track, quantify, and document NIH investments that lead up to drug commercialization Food and Drug Administration Initiatives to Advance Drug Development Innovation Janet Woodcock, M.D., Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA) The Public Sector Role in Drug Development Bhaven Sampat, Ph.D., Columbia University Gauging the Returns on Federally Funded Basic Research Danielle Li, Ph.D., Massachusetts Institute of Technology Sloan School of Management PREPUBLICATION COPY: UNCORRECTED PROOFS 59

60 ROLE OF NIH IN DRUG DEVELOPMENT INNOVATION Quantifying the Impact of NIH Funding on Pharmaceutical Innovation Margaret Blume Kohout, Ph.D., Gettysburg College Panel Discussion 12:00 pm Lunch Break 1:00 pm SESSION 3: Patent and Technology Transfer Policies in Promoting the Development and Commercialization of NIH-Conducted and Funded Medical Research Moderator: Stephen Merrill, Ph.D., Senior Fellow and former executive director, Center for Innovation Policy at Duke Law School Session Objective: To discuss the current state of technology transfer agreements and licensing, and models for spurring drug innovation Uncertainty About Patentable Subject Matter: Implications for Biomedical Research Arti Rai, J.D., Duke Law School Technology Transfer at U.S. Academic Institutions Today Ashley Stevens, Ph.D., Focus IP Group, LLC Reforming March-In Rights John Thomas, J.D., Georgetown University Improving the Technology Transfer Process Chuck Na, M.S., National Institute of Standards and Technology Panel Discussion 2:45 pm Break 3:00 pm SESSION 4: Strategies and Policies to Facilitate the Translation of Federally Funded Biomedical Research into Drug Development and Commercialization Moderator: Jennifer Moore, Ph.D., R.N., Institute for Medicaid Innovation and University of Michigan Medical School Session Objective: To examine ways to improve efficiency and lower the cost of clinical drug trials or other costly phases of drug development, and ways to incentivize translation of federally funded research discoveries into drug innovation Clinical Trials: Risks and Costs in Drug Development Steven Galson, M.D., M.P.H., Amgen PREPUBLICATION COPY: UNCORRECTED PROOFS

61 APPENDIX B Initiatives by the U.S. Department of Defense to Advance Drug Development Innovation Terry Rauch, Ph.D., M.P.H., M.B.A., U.S. Department of Defense Collaborating to Accelerate Medical Product Development Lynn Hudson, Ph.D., Critical Path Institute Strategies to Aid Repurposing of Compounds for Secondary Uses Christine Colvis, Ph.D., National Center for Advancing Translational Sciences, NIH Infrastructure in Drug Development Innovation David Dilts, Ph.D., M.B.A., Vanderbilt University and Oregon Health & Science University Panel Discussion 5:00 pm Wrap-Up and Open Discussion Ameet Sarpatwari, Ph.D., J.D., Harvard Medical School and Brigham and Women’s Hospital 5:30 pm Adjourn Day 1 THURSDAY, JULY 25, 2019 8:00 am Registration 8:30 am SESSION 5: Drug Pricing and Innovative Financing and Business Models Moderator: Patricia Danzon, Ph.D., University of Pennsylvania Session Objective: To discuss the economic implications of escalating drug costs and explore new ideas and opportunities, potential business models and financing structures to accelerate drug discovery and development Drug Pricing: The Components Patricia Danzon, Ph.D., University of Pennsylvania Consumer Perspective on Recent Prescription Drug Price Trends Leigh Purvis, M.P.A., AARP Public Policy Institute Innovative Drugs: Access to Medicaid Beneficiaries Doug Wirth, M.S.W., Amida Care PREPUBLICATION COPY: UNCORRECTED PROOFS

62 ROLE OF NIH IN DRUG DEVELOPMENT INNOVATION Innovative Financial and Business Models to Accelerate Drug Discovery and Development Kevin Outterson, LL.M., Boston University School of Law Panel Discussion 10:15am Break 10:30 am SESSION 6: Strategies and Policies to Ensure Affordable Access to Innovative Drugs That Have Benefited from Federal Investments Moderator: Reed Tuckson, M.D., Tuckson Health Connections, LLC Session Objective: To discuss new ideas and opportunities, and to explore potential public policies that should be implemented to ensure that the public has affordable access to innovative drugs that have benefited from federal investments Taxpayer Funded Drugs and a Pricing Crisis David Mitchell, Patients for Affordable Drugs New Ideas and Opportunities to Ensure That the Public Has Affordable Access to Innovative Drugs Tanisha Carino, Ph.D., FasterCures, Milken Institute Potential Ways to Reform the Patent System to Ensure That Patients Have Affordable Access to Innovative Drugs Tahir Amin, LL.B., Dip. LP., Initiative for Medicines, Access & Knowledge (I- MAK), Inc. Strategies and Policies Available to Bring About Transformative Reductions in the Increasing Prices of Drugs Aaron Kesselheim, M.D., J.D., M.P.H., Harvard Medical School and Brigham and Women’s Hospital Panel Discussion 12:30 pm Wrap-Up and Adjourn PREPUBLICATION COPY: UNCORRECTED PROOFS

The Role of NIH in Drug Development Innovation and Its Impact on Patient Access: Proceedings of a Workshop Get This Book
×
Buy Paperback | $60.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24–25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!